Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real-world study

IF 3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM Journal of Diabetes Investigation Pub Date : 2025-03-15 DOI:10.1111/jdi.70023

Yiming Wu, Ying Gao, Xiaohui Guo, Junqing Zhang, Ang Li

{"title":"Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real-world study","authors":"Yiming Wu, Ying Gao, Xiaohui Guo, Junqing Zhang, Ang Li","doi":"10.1111/jdi.70023","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>No studies have specifically examined the effects of finerenone in treating type 2 diabetes patients with chronic kidney disease (CKD) and microalbuminuria. This study aimed to evaluate the effectiveness of finerenone in this group of patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective real-world study (ChiCTR2400087169) included type 2 diabetes outpatients with CKD from the Peking University First Hospital between March 2023 and March 2024. All patients in this study had a urinary albumin-to-creatinine ratio (UACR) of 30–299 mg/g. The effects of finerenone were assessed by comparing UACR, HbA1c, creatinine, serum potassium, eGFR, and blood pressure at baseline and after treatment.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Sixty-four patients (39 males and 25 females), with a median age of 65.75 years and a median duration of T2DM of 15.21 years, were included. The baseline median UACR was 100.50 mg/g, significantly decreased to 61.27 mg/g (<i>P</i> < 0.001) at 3 months and 62.49 mg/g (<i>P</i> < 0.001) at 6 months after treatment. None of the other parameters differed significantly. Finerenone alone or in combination with ABS inhibitors, SGLT2 inhibitors, or GLP-1 agonists did not result in significant differences in UACR reduction. Patients with a >30% UACR decrease had significantly higher baseline systolic blood pressure (SBP) than those with a ≤30% decrease (<i>P</i> < 0.05). Furthermore, baseline SBP significantly decreased after 6 months of treatment in patients with a >30% UACR reduction (<i>P</i> < 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Finerenone is effective in treating type 2 diabetes with CKD and microalbuminuria. Improved SBP control leads to a greater UACR reduction.</p>\n </section>\n </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 6","pages":"1028-1033"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70023","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdi.70023","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

No studies have specifically examined the effects of finerenone in treating type 2 diabetes patients with chronic kidney disease (CKD) and microalbuminuria. This study aimed to evaluate the effectiveness of finerenone in this group of patients.

Methods

This retrospective real-world study (ChiCTR2400087169) included type 2 diabetes outpatients with CKD from the Peking University First Hospital between March 2023 and March 2024. All patients in this study had a urinary albumin-to-creatinine ratio (UACR) of 30–299 mg/g. The effects of finerenone were assessed by comparing UACR, HbA1c, creatinine, serum potassium, eGFR, and blood pressure at baseline and after treatment.

Results

Sixty-four patients (39 males and 25 females), with a median age of 65.75 years and a median duration of T2DM of 15.21 years, were included. The baseline median UACR was 100.50 mg/g, significantly decreased to 61.27 mg/g (P < 0.001) at 3 months and 62.49 mg/g (P < 0.001) at 6 months after treatment. None of the other parameters differed significantly. Finerenone alone or in combination with ABS inhibitors, SGLT2 inhibitors, or GLP-1 agonists did not result in significant differences in UACR reduction. Patients with a >30% UACR decrease had significantly higher baseline systolic blood pressure (SBP) than those with a ≤30% decrease (P < 0.05). Furthermore, baseline SBP significantly decreased after 6 months of treatment in patients with a >30% UACR reduction (P < 0.05).

Conclusions

Finerenone is effective in treating type 2 diabetes with CKD and microalbuminuria. Improved SBP control leads to a greater UACR reduction.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

芬尼酮治疗中国2型糖尿病合并慢性肾病伴微量白蛋白尿患者的有效性：一项回顾性现实世界研究

目的：目前还没有研究专门研究芬尼酮治疗2型糖尿病合并慢性肾脏疾病（CKD）和微量白蛋白尿的效果。本研究旨在评估芬烯酮在这组患者中的有效性。方法：这项回顾性现实世界研究（ChiCTR2400087169）纳入了2023年3月至2024年3月期间北京大学第一医院2型糖尿病合并CKD的门诊患者。本研究中所有患者的尿白蛋白与肌酐比值（UACR）为30-299 mg/g。通过比较基线和治疗后的UACR、HbA1c、肌酐、血清钾、eGFR和血压来评估芬烯酮的作用。结果：纳入64例患者（男39例，女25例），中位年龄65.75岁，中位T2DM病程15.21年。基线中位UACR为100.50 mg/g，显著降至61.27 mg/g (UACR降低30%的患者基线收缩压（SBP）明显高于UACR降低≤30%的患者（P < 30%）。结论：芬纳酮对2型糖尿病合并CKD和微量白蛋白尿有效。改善的收缩压控制导致更大的UACR降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Diabetes Investigation ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

9.40%

发文量

218

审稿时长

6-12 weeks

期刊介绍： Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).